The Ulster Hospital has become the first in the United Kingdom to provide a new injectable treatment for people with chronic obstructive pulmonary disease.

The drug, dupilumab, is administered every two weeks and targets the underlying inflammation that causes COPD flare-ups. By calming immune cells that drive lung inflammation, it aims to reduce severe exacerbations and limit the need for hospital admission.

Patients receive their first dose under clinical supervision and are then trained to inject themselves at home. The self-administration model gives individuals greater independence while they remain in regular contact with their respiratory team.

One recipient of the treatment, Samuel from Downpatrick, has lived with COPD for several years. He described the home injection as a convenient option, noting that he appreciates the backup support available from Downe Hospital if needed. It was his first dose, and he expressed hope that it would improve his condition.

Consultant respiratory physician Dr Richard Hewitt said COPD is a common condition that drives many hospital visits. He stated that the new medication offers a way to reduce lung inflammation and, in turn, cut down on exacerbations requiring antibiotics, steroids, or hospital care. The Ulster Hospital is leading uptake of the therapy in the UK.

Chronic obstructive pulmonary disease is a long-term lung condition that affects breathing. The South Eastern Trust, which runs the Ulster and Downe hospitals, provides acute services across the region.